Lunai Bioworks Inc. has finalized a $20 million transaction using Series B convertible preferred shares to acquire a portfolio of central nervous system (CNS) drug-delivery and neurotherapeutic patents from Neurobridge IP Holdings. The deal, closed on May 1, positions the company to expand its brain-disease treatment pipeline while addressing ongoing Nasdaq listing requirements.
The Sacramento, California-based biotechnology firm disclosed the acquisition on Monday, emphasizing that the transaction increases its stockholders' equity above the $2.5 million minimum threshold required for continued listing on the Nasdaq Capital Market. The company faces a hearings panel after previous delisting pressures. Nasdaq rules also mandate that the company's common shares maintain a minimum bid price of $1.00.
As of 1:45 p.m. PDT Monday, Lunai shares traded at $0.3246, with an intraday range of $0.43 to $0.2857. Approximately 99.1 million shares had changed hands, giving the company a market capitalization of roughly $7.6 million—well below the stated value of the preferred shares used in the transaction.
The deal did not involve any cash. According to an SEC filing, Lunai issued eight Series B convertible preferred shares with a total stated value of $20 million as merger consideration for Neurobridge. Of these, Oncotelic Inc. acquired five preferred shares valued at $12.5 million, while Pelerin Therapeutics Inc. took three shares worth $7.5 million.
Neurobridge IP Holdings was a shell entity with no employees, customer base, sales network, or revenue. The company held only patents and pending applications, with no facilities or trade names. Lunai confirmed that no cash exchanged hands in the transaction.
The acquired patent portfolio covers Alzheimer's compounds, anti-TGF-beta agents, various apomorphine formulations, and intranasal delivery technologies for neurological conditions. Lunai highlighted two key delivery platforms: a prodrug system designed to cross the blood-brain barrier, and a nose-to-brain method that bypasses the bloodstream. The blood-brain barrier is a protective mechanism that often impedes drug delivery to the brain.
CEO David Weinstein described the acquisition as combining "complementary CNS delivery approaches" aimed at addressing "persistent challenges in neurological drug development." The company sees potential applications in Alzheimer's projects, combination therapies, and 505(b)(2) regulatory filings for repurposed drugs, as well as CNS biodefense countermeasures requiring rapid brain delivery.
Common shareholders face a capital structure overhang. The Series B preferred shares can convert into up to 13,333,333 common shares at $1.50 each, subject to stockholder approval. However, Lunai stated that such approval is not on the agenda for the May 8 special meeting unless a separate proxy supplement is filed.
The patent deal does not resolve all listing uncertainties. Lunai warned that Nasdaq might still determine the company falls short on stockholders' equity, depending on how the preferred stock is accounted for. Other risks include the unresolved $1 bid-price requirement, potential delisting, and the possibility that the acquired patents could be invalid, unenforceable, or commercially insignificant.
Lunai is seeking shareholder approval for a reverse stock split ranging from 1-for-3 to 1-for-30, with the board deciding the final ratio. Management cautioned that even a split may not ensure the stock stays above the $1 minimum. The company operates through subsidiaries Renovaro Biosciences, Renovaro Cube, and BioSymetrics, and has yet to generate product sales revenue. It continues to require additional financing and may never achieve profitability.
